menu

A Look Behind the Curtain: Exploring Lower-Risk MDS-RS & MDS/MPN-RS-T

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Look Behind the Curtain: Exploring Lower-Risk MDS-RS & MDS/MPN-RS-T

3 chapters
Play All
0.25 credits
15 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Guillermo Garcia-Manero, MD

    Professor of Medicine, Department of Leukemia
    University of Texas MD Anderson Cancer Center
    Houston, TX 

    Research: AbbVie, APR, Astex, Bristol Myers Squibb, Curis, Genentech, Gilead, Novartis

    Rami Komrokji, MD
    Section Head, Leukemia & MDS
    Vice Chair, Malignant Hematology
    Moffitt Cancer Center
    Tampa, FL

    Consulting Fees: AbbVie, Acceleron, Bristol Myers Squibb/Celgene

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Employ a multidisciplinary approach when assessing clinical and pathologic disease characteristics of lower-risk myelodysplastic syndrome (MDS) to improve both the diagnosis and assessment of the durability of the treatment response in patients
    2. Apply validated criteria to hasten identification of patients with lower-risk MDS who have failed or are refractory to therapy with erythropoiesis-stimulating agents (ESAs)
    3. Incorporate evidence-based therapeutic options for patients with lower-risk MDS who are failing or refractory to ESA therapy
  • Target Audience

    This activity is designed to meet the educational needs of hematologists, hematologist/oncologists, pathologists, and hematopathologists in community and academic settings, as well as other healthcare providers interested in the treatment of MDS.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Expert Interview activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 credits AAPA Category 1 CME credits. Approval is valid until 09/08/2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Guillermo Garcia-Manero, MD

    Professor of Medicine, Department of Leukemia
    University of Texas MD Anderson Cancer Center
    Houston, TX 

    Research: AbbVie, APR, Astex, Bristol Myers Squibb, Curis, Genentech, Gilead, Novartis

    Rami Komrokji, MD
    Section Head, Leukemia & MDS
    Vice Chair, Malignant Hematology
    Moffitt Cancer Center
    Tampa, FL

    Consulting Fees: AbbVie, Acceleron, Bristol Myers Squibb/Celgene

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Employ a multidisciplinary approach when assessing clinical and pathologic disease characteristics of lower-risk myelodysplastic syndrome (MDS) to improve both the diagnosis and assessment of the durability of the treatment response in patients
    2. Apply validated criteria to hasten identification of patients with lower-risk MDS who have failed or are refractory to therapy with erythropoiesis-stimulating agents (ESAs)
    3. Incorporate evidence-based therapeutic options for patients with lower-risk MDS who are failing or refractory to ESA therapy
  • Target Audience

    This activity is designed to meet the educational needs of hematologists, hematologist/oncologists, pathologists, and hematopathologists in community and academic settings, as well as other healthcare providers interested in the treatment of MDS.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Expert Interview activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 credits AAPA Category 1 CME credits. Approval is valid until 09/08/2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Sep 2022
Webpack App